Abstract Objective To explore the clinical value of the renal phosphorus threshold (ratio of tubular maximum reabsorption of phosphate to glomerular filtration rate, TmP/GFR) in the diagnosis and treatment of children with X-linked hypophosphatemic rickets (XLH). Methods A retrospective study was conducted, including 83 children diagnosed with XLH at Children's Hospital of Nanjing Medical University from January 2010 to January 2023. Initial diagnosis and follow-up data were collected to investigate the correlation of TmP/GFR with the severity of rickets, calcium and phosphorus metabolism indicators, and the dosage of phosphate treatment. Children were divided into two groups based on the occurrence of renal calcification: the renal calcification group (n=47) and the non-renal calcification group (n=36). Clinical data between the two groups were compared. Multivariate logistic regression analysis was used to identify factors influencing renal calcification in XLH children. The predictive value of TmP/GFR for renal calcification in XLH children was evaluated using receiver operating characteristic (ROC) curves. Results In the 83 XLH children, the initial TmP/GFR was (0.78±0.21) mmol/L, with significant individual variation (range: 0.28-1.24 mmol/L). TmP/GFR showed no significant correlation with the severity of rickets (P>0.05). Parathyroid hormone was negatively correlated with TmP/GFR (rs=-0.020, P=0.008), while blood phosphorus (rs=0.384, P<0.001), blood calcium (rs=0.251, P<0.001), and 25-hydroxyvitamin D (rs=0.179, P<0.001) were positively correlated with TmP/GFR. No significant correlation was found between TmP/GFR and alkaline phosphatase (rs=-0.002, P=0.960) or phosphate treatment dosage (rs=0.012, P=0.800). Blood calcium and TmP/GFR levels were significantly lower in the renal calcification group than in the non-renal calcification group (P<0.05), while parathyroid hormone and urine calcium levels were significantly higher in the renal calcification group (P<0.05). Multivariate logistic regression analysis indicated that TmP/GFR and urine calcium levels were closely associated with renal calcification in XLH children (P<0.05). ROC curve analysis revealed that the areas under the curve for TmP/GFR, urine calcium, and their combined detection predicting renal calcification in XLH children were 0.696, 0.679, and 0.761, respectively. Conclusions TmP/GFR may serve as an important diagnostic indicator for pediatric XLH; however, it does not reflect the severity or activity of rickets and cannot be used to judge the efficacy of traditional treatment. Urine calcium and TmP/GFR are valuable predictors for renal calcification in XLH children.
Corresponding Authors:
Chen Y Email：xych0929@sina.com。
E-mail: xych0929@sina.com
Cite this article:
TAO Jia-Qi,CHEN Ying. Clinical value of renal phosphorus threshold in the diagnosis and treatment X-linked hypophosphatemic rickets in children[J]. CJCP, 2024, 26(9): 926-932.
TAO Jia-Qi,CHEN Ying. Clinical value of renal phosphorus threshold in the diagnosis and treatment X-linked hypophosphatemic rickets in children[J]. CJCP, 2024, 26(9): 926-932.
Kinoshita Y, Fukumoto S. X-linked hypophosphatemia and FGF23-related hypophosphatemic diseases: prospect for new treatment[J]. Endocr Rev, 2018, 39(3): 274-291. PMID: 29381780. DOI: 10.1210/er.2017-00220.
Imel EA, Glorieux FH, Whyte MP, et al. Burosumab versus conventional therapy in children with X-linked hypophosphataemia: a randomised, active-controlled, open-label, phase 3 trial[J]. Lancet, 2019, 393(10189): 2416-2427. PMID: 31104833. PMCID: PMC7179969. DOI: 10.1016/S0140-6736(19)30654-3.
Bijvoet OL. Relation of plasma phosphate concentration to renal tubular reabsorption of phosphate[J]. Clin Sci, 1969, 37(1): 23-36. PMID: 5822530.
Kruse K, Hinkel GK, Griefahn B. Calcium metabolism and growth during early treatment of children with X-linked hypophosphataemic rickets[J]. Eur J Pediatr, 1998, 157(11): 894-900. PMID: 9835432. DOI: 10.1007/s004310050962.
Hamdy NAT, Harvengt P, Usardi A. X-linked hypophosphatemia: the medical expert's challenges and the patient's concerns on their journey with the disease[J]. Arch Pediatr, 2021, 28(7): 612-618. PMID: 34593293. DOI: 10.1016/j.arcped.2021.09.005.
Guven A, Al-Rijjal RA, BinEssa HA, et al. Mutational analysis of PHEX, FGF23 and CLCN5 in patients with hypophosphataemic rickets[J]. Clin Endocrinol (Oxf), 2017, 87(1): 103-112. PMID: 28383812. DOI: 10.1111/cen.13347.
Beck-Nielsen SS, Brixen K, Gram J, et al. Mutational analysis of PHEX, FGF23, DMP1, SLC34A3 and CLCN5 in patients with hypophosphatemic rickets[J]. J Hum Genet, 2012, 57(7): 453-458. PMID: 22695891. DOI: 10.1038/jhg.2012.56.
Wang S, Wang X, He M, et al. Efficacy and safety of burosumab in X-linked hypophosphatemia[J]. J Clin Endocrinol Metab, 2023, 109(1): 293-302. PMID: 37497620. DOI: 10.1210/clinem/dgad440.
Derain Dubourg L, Aurelle M, Chardon L, et al. Tubular phosphate handling: references from child to adulthood in the era of standardized serum creatinine[J]. Nephrol Dial Transplant, 2022, 37(11): 2150-2156. PMID: 34850142. DOI: 10.1093/ndt/gfab331.
Holm IA, Nelson AE, Robinson BG, et al. Mutational analysis and genotype-phenotype correlation of the PHEX gene in X-linked hypophosphatemic rickets[J]. J Clin Endocrinol Metab, 2001, 86(8): 3889-3899. PMID: 11502829. DOI: 10.1210/jcem.86.8.7761.
Igaki JM, Yamada M, Yamazaki Y, et al. High iFGF23 level despite hypophosphatemia is one of the clinical indicators to make diagnosis of XLH[J]. Endocr J, 2011, 58(8): 647-655. PMID: 21597229. DOI: 10.1507/endocrj.k10e-257.
Keskin M, Sava?-Erdeve ?, Sa?sak E, et al. Risk factors affecting the development of nephrocalcinosis, the most common complication of hypophosphatemic rickets[J]. J Pediatr Endocrinol Metab, 2015, 28(11-12): 1333-1337. PMID: 26203600. DOI: 10.1515/jpem-2014-0447.
